Welcome!

News Feed Item

Data Published in Nature Biotechnology Show Messenger (m)RNA Prophylactic Vaccines Based on CureVac's RNActive® Technology Demonstrate Immunogenicity and Protection Against Influenza Virus Infection

-- RNActive Vaccine Technology Allows Fast Production in Response to a Pandemic Scenario

TUEBINGEN, Germany, Nov. 25, 2012 /PRNewswire/ -- CureVac GmbH, a clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, and the German Federal Research Institute for Animal Health, Friedrich-Loeffler-Institute (FLI), Germany, today announced that mRNA vaccines (RNActive) based on the company's RNA technology platform have the potential to provide effective protection against infectious diseases. In vivo data published by CureVac and the Friedrich-Loeffler-Institute online in Nature Biotechnology show that mRNA vaccines induced balanced, long-lived and protective immunity to influenza A virus infections in various animal models. It is also shown that the production of RNActive vaccines is highly flexible. Thus, RNActive vaccines can be rapidly supplied for a variety of virus strains and subtypes identified in response to pandemic scenarios.

"The findings and results from a very fruitful collaboration with our colleagues from the renowned Friedrich-Loeffler-Institute, underscore the medical potential of mRNA beyond cancer immunotherapy and validate the capacity of our RNActive vaccines to prevent infectious diseases," said Ingmar Hoerr, Ph.D., Chief Executive Officer of CureVac. "The synthetic nature of our RNActive vaccines reduces production time dramatically and allows for sequence-matched vaccines that can be produced quickly and reliably in a scalable process. Additionally, our vaccines can be stored at room temperature, thereby avoiding the cold-chain in contrast to all other vaccines on the market and making worldwide distribution of our vaccines logistically and financially attractive."

Lothar Stitz, M.D., Head of Institute of Immunology, FLI, Greifswald, Germany, and one of the corresponding authors of the publication, said, "Our data highlight the potential and advantages of prophylactic mRNA-based vaccines and make immunization against a broad range of pathogens possible. We have a significant need for improved technologies that could be rapidly adapted to match circulating strains and allow efficient, large-scale production if necessary. In particular, we ultimately need a broadly protective vaccine against influenza. Thus, these mRNA vaccines overcome the draw-backs of many other prophylactic vaccination methods including DNA-based approaches that can have insufficient clinical efficacy or safety and may cause residual vector immunogenicity."

The authors demonstrated that the mRNA vaccine encoding full-length hemagglutinin (HA) of the influenza A/PuertoRico/8/1934 (PR8HA) strain was immunogenic and induced balanced B- and T-cell responses in mice. Influenza A viruses are classified based on the expression of a certain subtype of HA and a certain subtype of neuraminidase (NA). HA forms the basis of all licensed influenza vaccines. Furthermore, the immunized mice were protected against death and disease upon infectious challenge by an antibody-dependent mode-of-action. Moreover, the authors targeted additional influenza A virus strains by sequence-matched, HA-specific vaccines, and showed that all vaccines induced full protection against lethal infections, including H1N1pdm09 swine flu and H5N1 bird flu virus. The mRNA vaccine was immunogenic and provided long-term protection in newborn as well as in aged mice.

Additional data revealed that full protection was achieved upon single-dose immunization against influenza A/PR8 with a multi-component HA and NA mRNA vaccine. Furthermore, mRNA vaccines provided heterologous protection; vaccination with PR8 nucleoprotein (NP) mRNA led to protection against homologous PR8 (H1N1) or heterologous MB1 (H5N1) virus. Moreover, mRNA vaccines provided immunogenicity in ferrets, the animal model of choice for preclinical proof-of-concept studies in influenza research, and pigs compared to a licensed trivalent vaccine of corresponding specificity.

The publication, entitled 'Protective efficacy of in vitro synthesized, specific messenger RNA vaccines against influenza A virus infection,' was published online in Nature Biotechnology on Nov. 25.

About RNActive
CureVac is combining both the antigenic and adjuvant properties of mRNAs to develop novel and effective mRNA vaccines. RNActive vaccines are comprised of modified and formulated mRNA with three distinct features: The mRNA vaccines are translated into the target antigens, and the formulation and modifications lead to translatability ensuring (1) strong antigen expression, (2) increased stability and (3) enhanced immune-stimulatory activity.

About CureVac
CureVac is developing an entirely new class of therapies based on a fundamental new understanding of the medical potential of mRNA. Using its RNA technology platform, CureVac is currently developing novel therapeutic mRNA vaccines (RNActive) for cancer and prophylactic vaccines for infectious diseases and adjuvants based on long, non-coding RNAs (RNAdjuvant®) for enhancing the immune response of other vaccines. The company has successfully completed Phase 1/2a studies with its RNActive cancer vaccines in prostate cancer and non-small cell lung cancer (NSCLC). Results so far have shown that mRNA-based products are safe and capable of inducing balanced immune responses including humoral and cellular, Th1 and Th2 and effector and memory responses. In addition to developing its own pipeline, CureVac is collaborating with Sanofi Pasteur and In-Cell-Art on a $33.1 million project co-funded by Defense Advanced Research Projects Agency (DARPA) for the development of prophylactic vaccines in infectious diseases utilizing its RNActive technology platform. For more information, please visit: http://www.curevac.com.

Media Contacts                                                                      
Martina Schwarzkopf, Ph.D.  
Tony Russo, Ph.D.                                        
Russo Partners                                                                     
T: + 1 (212) 845 4292
M: + 1 (347) 591 8785                                    
T: + 1 (212) 845 4251
[email protected]   
[email protected]    

Marina Bulach, Executive Assistant
CureVac GmbH
T: + 49 (7071) 920 53 20
[email protected]  

 

SOURCE CureVac

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
21st International Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Me...
Join us at Cloud Expo June 6-8 to find out how to securely connect your cloud app to any cloud or on-premises data source – without complex firewall changes. More users are demanding access to on-premises data from their cloud applications. It’s no longer a “nice-to-have” but an important differentiator that drives competitive advantages. It’s the new “must have” in the hybrid era. Users want capabilities that give them a unified view of the data to get closer to customers and grow business. The...
"We focus on composable infrastructure. Composable infrastructure has been named by companies like Gartner as the evolution of the IT infrastructure where everything is now driven by software," explained Bruno Andrade, CEO and Founder of HTBase, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
SYS-CON Events announced today that Cloud Academy named "Bronze Sponsor" of 21st International Cloud Expo which will take place October 31 - November 2, 2017 at the Santa Clara Convention Center in Santa Clara, CA. Cloud Academy is the industry’s most innovative, vendor-neutral cloud technology training platform. Cloud Academy provides continuous learning solutions for individuals and enterprise teams for Amazon Web Services, Microsoft Azure, Google Cloud Platform, and the most popular cloud com...
"We are a monitoring company. We work with Salesforce, BBC, and quite a few other big logos. We basically provide monitoring for them, structure for their cloud services and we fit into the DevOps world" explained David Gildeh, Co-founder and CEO of Outlyer, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Automation is enabling enterprises to design, deploy, and manage more complex, hybrid cloud environments. Yet the people who manage these environments must be trained in and understanding these environments better than ever before. A new era of analytics and cognitive computing is adding intelligence, but also more complexity, to these cloud environments. How smart is your cloud? How smart should it be? In this power panel at 20th Cloud Expo, moderated by Conference Chair Roger Strukhoff, paneli...
DevOps at Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to w...
The current age of digital transformation means that IT organizations must adapt their toolset to cover all digital experiences, beyond just the end users’. Today’s businesses can no longer focus solely on the digital interactions they manage with employees or customers; they must now contend with non-traditional factors. Whether it's the power of brand to make or break a company, the need to monitor across all locations 24/7, or the ability to proactively resolve issues, companies must adapt to...
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
Cloud Expo, Inc. has announced today that Andi Mann and Aruna Ravichandran have been named Co-Chairs of @DevOpsSummit at Cloud Expo Silicon Valley which will take place Oct. 31-Nov. 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. "DevOps is at the intersection of technology and business-optimizing tools, organizations and processes to bring measurable improvements in productivity and profitability," said Aruna Ravichandran, vice president, DevOps product and solutions marketing...
The current age of digital transformation means that IT organizations must adapt their toolset to cover all digital experiences, beyond just the end users’. Today’s businesses can no longer focus solely on the digital interactions they manage with employees or customers; they must now contend with non-traditional factors. Whether it's the power of brand to make or break a company, the need to monitor across all locations 24/7, or the ability to proactively resolve issues, companies must adapt to...
SYS-CON Events announced today that CA Technologies has been named "Platinum Sponsor" of SYS-CON's 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CA Technologies helps customers succeed in a future where every business - from apparel to energy - is being rewritten by software. From planning to development to management to security, CA creates software that fuels transformation for companies in the applic...
SYS-CON Events announced today that IBM has been named “Diamond Sponsor” of SYS-CON's 21st Cloud Expo, which will take place on October 31 through November 2nd 2017 at the Santa Clara Convention Center in Santa Clara, California.
We build IoT infrastructure products - when you have to integrate different devices, different systems and cloud you have to build an application to do that but we eliminate the need to build an application. Our products can integrate any device, any system, any cloud regardless of protocol," explained Peter Jung, Chief Product Officer at Pulzze Systems, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA
Hardware virtualization and cloud computing allowed us to increase resource utilization and increase our flexibility to respond to business demand. Docker Containers are the next quantum leap - Are they?! Databases always represented an additional set of challenges unique to running workloads requiring a maximum of I/O, network, CPU resources combined with data locality.